BI 2536 is a potent, ATP-competitive PLK1 inhibitor. It affects Wnt/β-catenin and MEK/ERK signaling by binding to the kinase ATP-binding site, effectively inducing G2/M cell cycle arrest and apoptosis, and inhibiting cancer cell proliferation.
BI 2536: Mechanism of Action
BI 2536 MOA：Targeting PLK1/Cell Cycle Pathway for Oncology Research
Jump to
- BI 2536 Clinical Trials
- BI 2536 Working Concentration | Cell Culture | Treatment
- BI 2536 Solubility in DMSO
- BI 2536 Stock Solution
- BI 2536 Storage
- BI 2536 Stability
- BI 2536 Combination Database
- BI 2536 Molecular Weight
- BI 2536 SMILES
- BI 2536 CAS Number
- BI 2536 Chemical Structure (2D and 3D)
- BI 2536 IC50 for Cell-based and Cell-free Assays
- BI 2536 Sigma (SML4229)? Try a better option.
- BI 2536 MedChemExpress (HY-50698)? Try a better option.
- BI 2536 Cayman (17385)? Try a better option.
- BI 2536 CST (26744)? Try a better option.
- BI 2536 SDS｜MSDS